ADVERTISEMENT
StartUps and SMEs
Private Company Edition: Abcuro’s series C venture capital round will fund its lead drug through pivotal results, filing with the US FDA and launch preparations. Also, AdvanCell completed a $112m series C round, Lutris Pharma raised $30m and Imvax closed a $29m financing.
The Centre for Commercialization of Regenerative Medicine has spent over a decade crafting a cell and gene therapy ecosystem in Canada. Now it is replicating the model abroad.
During Q4, biopharmas brought in an aggregate $16.8bn in financing and device company fundraising totaled $2.3bn; while in vitro diagnostic firms and research tools players raised $294m.
Boston-area biotech Apnimed expects Phase III readouts for its obstructive sleep apnea combination drug by May. Patients with OSA are desperate for a pill to treat the condition, and GLP-1 agonists are only part of the solution.
Private Company Edition: Given the number of start-ups with clinical-stage assets and investors’ concerns that programs are appropriately funded, the trend toward $100m-plus VC rounds is likely to continue. Also, Lilly and a16z launched a new VC fund with up to $500m.
Evaluate data from the fourth quarter of 2024 show another period of venture capital fundraising that beat each quarter of 2023, as $100m-plus mega-rounds surged.
The J.P. Morgan Healthcare Conference and Biotech Showcase revealed what investors are really thinking about the health of the capital markets this year.
Scrip used the J.P. Morgan Healthcare Conference and Biotech Showcase to speak with investors and gauge the health of the capital markets this year.
CHARM Therapeutics' CEO discusses its DragonFold technology, applying AI to cancer drug hunting, and the benefits of its Nobel Prize-winning roots.
The UK market has become tougher for smaller innovators, says Andy Mears, CEO of Deltex Medical, which plans to launch a new iteration of its minimally invasive ultrasound-based technology, the oesophageal Doppler monitor. He explained how market access challenges have steepened.